

Supplement to the prospectus relating to the invitation to subscribe for shares in Oncology Venture Sweden AB

About the supplementary prospectus

This prospectus supplement is a supplement to the prospectus relating to the offer to subscribe for shares in Oncology Venture Sweden AB, which has been prepared by the Board of Oncology Venture Sweden AB ("Oncology Venture"), corporate registration number 559016-3290. The company conducts a rights issue with subscription period January 11th – January 25th, 2018. The public is also given the opportunity to subscribe for shares in the rights issue. The Prospectus was approved and registered by the Swedish Financial Supervisory on January 4th, 2018. Financial Supervisory registration number is 17-20723. The prospectus was published on January 4th, 2018 and is available on the company's and AktieTorget's websites (www.oncologyventure.com and www.aktietorget.se).

The supplementary prospectus is a part of and should be read as part of the prospectus. The supplementary prospectus has been prepared in accordance with Chapter 2. 34 § The Act (1991: 980) regarding trading with financial instruments ("FITA") and was on January 12th, 2018 approved and registered by the Swedish Financial Supervisory Authority. Financial Supervisory registration number of the prospectus supplement is 18-517. Date of publication of the prospectus supplement is January 12th, 2018.

This supplementary prospectus has been prepared due to:

- Oncology Venture, on January 8th, 2018, after the Financial Supervisory Authority approved Oncology Venture's prospectus, issued a press release that the company's CFO, Nikolaj Buhl Jensen, had utilized 100,000 subscription warrants of series 2015/2018, which had contributed with SEK 740,000 to the company.

The additional information is added in Oncology Ventures prospectus on the following pages:

Page 8, C.3 "Aktier der er emitterede og indbetalte"

The following sentence is added in the prospectus after the sentence "Samtlige aktier er emitterede og fuldt indbetalte": Bemærk dog, at 100 000 warrants i serie 2015/2018 er blevet udnyttet, hvilket betyder at 107 000 aktier er registreret hos Svenske Selskabsstyrelsen (Bolagsverket). Efter registrering hos Bolagsverket vil antallet af aktier udgøre 11 087 573.

Page 27, "The offering in summary"

The following information is replaced in the prospectus: In the post "Number of shares before the new share issue" is "10,980,573 shares" replaced with "10,980,573 shares*".

The following information is added on the bottom of page 27: *Please note that 100,000 subscription warrants of series 2015/2018 has been utilized, meaning that 107,000 shares will be issued. After registration at Bolagsverket will the amount of shares be 11,087,573 shares.

Page 48, "Employees and management of research"

Current text in the prospectus concerning the amount of shares and share options owned by Nikolaj Buhl Jensen is replaced with the text below:

- Owns 124,013 shares of Oncology Venture Sweden AB privately and via the wholly-owned company Buhl Info ApS
- Does not hold any subscription warrants in Oncology Venture Sweden AB

Page 61, "Significant changes in financial position"

Current text in the prospectus is replaced with the following: In January 2018 a total of 100,000 subscription warrants of series 2015/2018 were utilized, meaning that 107,000 shares were issued. Oncology Venture has received SEK 740,000 through the utilizing of the share options of series 2015/2018.

Page 63, under "Developments concerning share capital"

Current table in the prospectus is replaced with the table below:

Year	Event	Price per share	Quota value (par value)	Increase in number of shares	Increase of share capital	Total number of shares	Total share capital
------	-------	-----------------	-------------------------	------------------------------	---------------------------	------------------------	---------------------

2015	Company Formation	-	0,14	3 586 166	502 063,24	3 586 166	502 063,24
2015	Issuance of shares for non-cash consideration	SEK 6.52	0,14	807 020	112 982,80	4 393 186	615 046,04
2015	Issuance of new shares	SEK 7.40	0,14	2 840 000	397 600,00	7 233 186	1 012 646,04
2016	Issuance of new shares	SEK 10.00	0,14	2 066 624	289 327,36	9 299 810	1 301 973,40
2016	Issuance of new shares	SEK 29.00	0,14	774 984	108 497,76	10 074 794	1 410 471,16
2017	Issuance of new shares	SEK 42.00	0,14	802 213	112 309,82	10 877 007	1 522 780,98
2017	Redemption of warrants/options	SEK 10.00	0,14	100 000	14 000,00	10 977 007	1 536 780,98
2017	Redemption of warrants/options	SEK 8.34	0,14	3 566	499,24	10 980 573	1 537 280,22
2018	Redemption of warrants/options	SEK 6,88	0,14	107 000	14 980,00	11 087 573	1 552 260,22
2018	Issuance of new shares*	SEK 16,30	0,14	2 745 143	384 320,02	13 832 716	1 936 580,24

* Assuming a fully subscribed new share issue.

Page 64, under "Outstanding stock option programs"

Under the section "Option Program 1" the following information is added: In January 2018 a total of 100,000 subscription warrants were utilized within the boundaries of Option Program 1. At the time of this prospectus is thus 70,000 subscription warrants outstanding.

Page 70, under "Miscellaneous"

The first bullit point in the prospectus is replaced with the following: At the time of this prospectus, there is a record at Bolagsverket concerning "Increase of share capital through exchange of convertible or subscription through warrant rights" since 100,000 subscription warrants of series 2015/2018 have been utilized in January 2018.

Right to withdraw

Investors who before the publication of the supplement prospectus, has subscribed for shares in the ongoing rights issue as described in the prospectus, in accordance with Chapter 2. 34 § Trading Act, have the right to withdraw their subscription of shares within two working days of publication of this prospectus, that is, by January 16th, 2018. Timing or terms and conditions are not affected of this prospectus supplement.

Delivery of the prospectus supplement

The Board of Oncology Venture Sweden AB hereby delivers prospectus supplement. Supplementary prospectus is available on the company's and AktieTorget's websites (www.oncologyventure.com and www.aktietorget.se).

Hørsholm, January 12th, 2018

The Board of Oncology Venture Sweden AB

Duncan Moore – Chairman of the Board

Sanjeevi Carani – Board Member

Steen Knudsen – Board Member

Ulla Hald Buhl – Board Member

Peter Birk – Board Member